Novocure Ltd. has announced the forthcoming presentation of final secondary endpoint results from the Phase 3 PANOVA-3 trial. This trial evaluates the use of Tumor Treating Fields (TTFields) therapy in conjunction with gemcitabine and nab-paclitaxel for patients with unresectable, locally advanced pancreatic cancer. The data will be shared as a late-breaking abstract during an oral presentation at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2025, scheduled to occur from July 2 to July 5 in Barcelona, Spain. The PANOVA-3 trial demonstrated a statistically significant improvement in median overall survival for patients treated with TTFields, as well as a delay in pain progression and preserved quality of life. TTFields therapy was well-tolerated, with mild to moderate skin adverse events being the most common device-related issues. Novocure plans to submit a premarket application for TTFields therapy to the FDA in the second half of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.